Illumina, Inc. $ILMN Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 87,976 shares of the life sciences company’s stock after selling 1,442 shares during the period. MetLife Investment Management LLC’s holdings in Illumina were worth $6,980,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Integrated Wealth Concepts LLC boosted its position in shares of Illumina by 10.1% in the 4th quarter. Integrated Wealth Concepts LLC now owns 3,291 shares of the life sciences company’s stock valued at $440,000 after purchasing an additional 301 shares during the period. Northern Trust Corp raised its stake in shares of Illumina by 26.9% during the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company’s stock worth $220,882,000 after purchasing an additional 349,878 shares in the last quarter. Lido Advisors LLC raised its stake in shares of Illumina by 18.1% during the 4th quarter. Lido Advisors LLC now owns 3,392 shares of the life sciences company’s stock worth $453,000 after purchasing an additional 521 shares in the last quarter. Keel Point LLC purchased a new stake in shares of Illumina during the 4th quarter worth about $204,000. Finally, Arohi Asset Management PTE Ltd. raised its stake in shares of Illumina by 91.9% in the 4th quarter. Arohi Asset Management PTE Ltd. now owns 121,270 shares of the life sciences company’s stock valued at $16,205,000 after acquiring an additional 58,070 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Up 0.8%

ILMN stock opened at $99.54 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The stock has a market capitalization of $15.30 billion, a P/E ratio of 12.60, a P/E/G ratio of 2.22 and a beta of 1.37. The business has a 50-day moving average of $98.74 and a 200-day moving average of $88.71. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Stephens set a $110.00 price target on Illumina and gave the stock an “overweight” rating in a research report on Monday, August 4th. Scotiabank lowered Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective on the stock. in a report on Friday, July 11th. Royal Bank Of Canada boosted their price target on Illumina from $118.00 to $126.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Citigroup lowered Illumina from a “hold” rating to a “strong sell” rating and reduced their price objective for the stock from $85.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Daiwa America lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Six analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $123.17.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.